ClearPoint Neuro (CLPT) Return on Capital Employed (2012 - 2026)

ClearPoint Neuro has disclosed Return on Capital Employed across 14 years of filings, most recently posting 30.75% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 30.75%, up 4734.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 30.75% (up 4734.0% YoY), and the FY2025 annual result was 41.88%, up 2267.0% from the prior year.
• Return on Capital Employed came in at 30.75% for Q1 2026 at ClearPoint Neuro, up from 35.39% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 25.22% in Q1 2022 to a low of 78.09% in Q1 2025.
• The 5-year median for Return on Capital Employed is 48.43% (2024), against an average of 46.91%.
• Across the five-year window, Return on Capital Employed sank 2989 bps in 2023 and soared 4734 bps in 2026, its largest moves.
• ClearPoint Neuro's Return on Capital Employed stood at 32.78% in 2022, then slumped by 91 bps to 62.67% in 2023, then declined by 7 bps to 67.26% in 2024, then soared by 47 bps to 35.39% in 2025, then gained by 13 bps to 30.75% in 2026.
• The last three Return on Capital Employed figures came in at 30.75% (Q1 2026), 35.39% (Q4 2025), and 42.49% (Q3 2025), per Business Quant data.